Cloning and expression of recombinant hirudin in CHO cell line
Subject Areas :
Journal of Comparative Pathobiology
, A. Sharifzadeh
1
,
, M. Heidari
2
,
, F. Aali
3
1 - .Department of Microbiology, Faculty of Veterinary Medicine, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran.
2 - Biotechnology Research Center, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran
3 - Biotechnology Research Center, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran
Received: 2020-11-07
Accepted : 2020-11-07
Published : 2020-05-21
Keywords:
Hirudn,
Cloning,
gene expression,
Abstract :
Hirudin is a 65-66 amino acids polypeptide which is secreted as an anticoagulant compound from salivary glands of medical leech. This drug is a very potent inhibitor of thrombin and is so effective for arterial and venous thrombosis prevention. The aim of the present research was to clone and express of hirudin gene in CHO cell line as a eukaryotic host cell. In this experimental study, a 221 bp fragment of hirudin gene was cloned into pcDNA3.1(+) vector. The pcDNA3.1(+)-hirudin recombinant vector was transfected into CHO cells by lipofectamine 2000 reagent. The eukaryotic expression of hirudin was evaluated by RT-PCR method. The pcDNA3.1(+)-hirudin recombinant vector was confirmed by PCR and enzymatic double digestion. Our findings showed that the mammalian expression of hirudin was successful. As, a 221 bp fragment corresponded to hirudin mRNA was observed on agarose gel after RT-PCR. The pcDNA3.1(+)-hirudin recombinant vector was constructed in this research successfully. This new recombinant plasmid can express the hirudin mRNA in CHO cells. Therefore, the recombinant protein that produced from this research can be a recombinant vaccine that could be applied for future research. Additionally, this construct has the potential to be use as DNA vaccine in next experiments.
References:
Barzegar A. Azizi A. Faridi P. Mohagheghzadeh A. Leech therapy in Iranian traditional medicine. Forsch. Komplementmed.2015. 22(1):50-53
Kalender M.E. Comez G. Sevinc A. Dirier A. Camci C. Leech therapy for symptomatic relief of cancer pain. Pain. Med.2010. 11(3):443-445.
Brzezinski P. Solovan C. Chiriac A. Foia L. Positive outcome of medical leeches (hirudotherapy) for venous congestion. Malawi. Med. J.2015. 27(1):38-39.
Sobczak N. Kantyka M. Hirudotherapy in veterinary medicine. Ann. Parasitol.2014. 60(2):89-92.
Abdualkader A.M. Ghawi A.M. Alaama M. Awang M. Merzouk A. Leech therapeutic applications. Indian J. Pharm. Sci.2013. 75(2):127-137.
Singh A.P. Medicinal leech therapy (hirudotherapy): a brief overview. Complement. Ther. Clin. Pract.2010. 16(4):213-215.
O'Dempsey T. Leeches--the good, the bad and the wiggly. Paediatr. Int. Child. Health.2012. 32(2):16-20.
Sawhney R. Juneja R. Rawat R.S. Mehta Y. Trehan N. Off-pump cardiac surgery (OPCAB) in a patient with recent leech therapy. Ann. Card. Anaesth.2012. 15(1):83-85.
Heydari M.R. Valipoor S. Leech Therapy and Cardio Vascular system . j. Cardiovas. Nurs.2016. 5(2):27-34.
Kumura T.Hino M.Yamane T.Tatsumi N. Hirudin as anticoagulant for both haematology and chemistry yest. J . Automated method manage in chem.2000.22(4).109-112.
Mergulhão F.J. Summers D.K. Monteiro G.A. Recombinant protein secretion in Escherichia coli. Biotechnol. Adv.2005. 23(3):177-202.
Corral-Rodriguez M.A. Macedo-Ribeiro S. Pereira P.J. Fuentes-Prior P. Leech-derived thrombin inhibitors: from structures to mechanisms to clinical applications. J. Med. Chem.2010. 53(10):3847-3861.
Cherniack E.P. Bugs as drugs, part two: worms, leeches, scorpions, snails, ticks, centipedes, and spiders. Altern. Med. Rev.2011. 16(1):50-58.
Sohn J.H. Kang H.A. Rao K.J. Kim C.H. Choi E.S. Chung B.H. Rhee S.K. Current status of the anticoagulant hirudin: it
biotechnological production and clinical practice. Appl. Microbiol. Biotechnol.2001. 57(5-6):606-613.
Halabian R. Shagerdi Esmaili N. Oodi A. Masroori N. Amirizadeh N .Mousavi Hosseini Gharehbaghian A. Rezvan H. Jalili M Habibi Rudkenar M.Isolation,cloning and expression of recombinant human factor VII in CHO cell line.Blood .2009. 6(1): 1-11.
Elliott J M. Kutschera U. Medicinal leeches: historical use, ecology, genetics and conservation.2011.Fresh water Review. 4: 21-41.
Rinas U. Hoffmann F. Betiku E. Estape D. Marten S. Inclusion body anatomy and functioning of chaperone-mediated in vivo inclusion body disassembly during high-level recombinant protein production in Escherichia coli. J. Biotechnol.2007. 127(2): 244-257.
Jagannadha rao K.Chul-hao K.sang-Ki R.Stastical 0ptimization of the medium for the production of recombinant hirudin from saccharomyces cervisiae using response surface methodology . process bio.200.35:639-647.
Sabaghzadeh S. Mirzahoseini H. Shahbazzadeh D. Naji T.Designing and Constructing Clone for Extracellular Expression of the Desirudin Anticoagulant Drug in E.coli. J Mazandaran Univ Med Sci 2014. 24(119): 72-82.
Baneyx F. Recombinant protein expression in Escherichia coli. Curr. Opin. Biotechnol. 1999.10(5):411-421.
Sig A.Guney M. Guclu A.Ozmen E.Medical leech therapy-an overall perspective.int med res.2017.7:1-6.
Haina Q.Zhilong X.Daijia Z.Yongming B.Xiaohai L.Guozhuu H.PEYGylation of hirudin and analysis of its antithrombin activity in vitro.Chin.J.Chem.Eng. 2007. 15(4):586-590.
_||_